HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

OTC Naloxone May Get Another Push From US FDA As Agency Prepares Novel Switch Proposed Rule

Executive Summary

Financial model isn't adequate currently, FDA Commissioner Robert Califf says, and agency may make regulatory changes to motivate sponsors.

You may also be interested in...



US FDA Commissioner Admonishes Health Care Stakeholders To Know Agency Better, Help More

Califf was candid during Science Board meeting about agency’s limits, such as disseminating accurate information in response to rampant misinformation during COVID-19 pandemic. “We need to call out people who are outside the FDA … because this vast universe of information out there is way bigger than we can handle on our own,” he said.

US FDA Considering Opioid Mail-Back Envelope Mandate, But Industry Has Heard This Before

Sponsors would be required to furnish patients with pre-paid envelopes to mail back unused opioid medications for disposal. Comments on FDA's proposal could follow industry concerns about burden on health care system voiced when the idea was floated in 2018.

Califf Says Opioid Labeling Changes, Withdrawals Still Possible

The US FDA commissioner also suggests the pain medications along with marijuana products should be regulated differently than other drugs.

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

RS152474

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel